Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Autor: Aghdami, Naser, Agüera-Morales, Eduardo, Ali, Rehiana, Allan, David, Arab, Leila, Battaglia, Mario, Berry, Isabelle, Blinkenberg, Morten, Bonetti, Bruno, Brundin, Lou, Capelli, Chiara, Castellan, Lucio, Cellerino, Maria, Cencioni, Maria Teresa, Clanet, Michel, Comi, Giancarlo, Courtman, David, Dazzi, Francesco, Fischer-Nielsen, Anne, Fernandez, Oscar, Fernandez, Victoria, Freedman, Mark S., Furlan, Roberto, Gimona, Mario, Gualandi, Francesca, Guan, Qingdong, Iacobaeus, Ellen, Inglese, Matilde, Introna, Martino, Izquierdo, Guillermo, Karimi, Shahedeh, Laroni, Alice, Le Blanc, Katarina, Loaiza, Sandra, Mallik, Shahrukh, Marley, Stephen, Marrie, Ruth Ann, Marriot, James, Martino, Gianvito, Nabavi, Seyed Massood, Miller, David, Muraro, Paolo A., Nicholas, Richard, Oliveri, Roberto S, Orengo, Giovanni, Palanicawande, Renuka, Pardini, Matteo, Radue, Ernst W, Ramo Tello, Cristina, Rush, Carolina, Schiavetti, Irene, Sellner, Johann, Sensebe, Luc, Soelberg Sorensen, Per, Sormani, Maria Pia, Strunk, Dirk, Szwajcer, David, Thalamas, Claire, Uccelli, Antonio, Wuerfel, Jens Thomas, Battaglia, Mario Alberto, Marriott, James, Muraro, Paolo, Radue, Ernst, Sorensen, Per Soelberg, Freedman, Mark S **
Zdroj: In The Lancet Neurology November 2021 20(11):917-929
Databáze: ScienceDirect